Investors sold shares of Amgen Inc. (NASDAQ:AMGN) on strength during trading on Thursday. $61.42 million flowed into the stock on the tick-up and $86.05 million flowed out of the stock on the tick-down, for a money net flow of $24.63 million out of the stock. Of all stocks tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $0.94 for the day and closed at $164.19

AMGN has been the subject of several research analyst reports. Vetr upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating and set a $175.53 price objective for the company in a research note on Monday, May 9th. Morgan Stanley boosted their price target on shares of Amgen from $193.00 to $195.00 in a research note on Friday, April 8th. Zacks Investment Research lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Wednesday, March 30th. Jefferies Group restated a “buy” rating and set a $187.00 price target on shares of Amgen in a research note on Wednesday, July 13th. Finally, Leerink Swann restated a “hold” rating on shares of Amgen in a research note on Sunday, June 26th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company. Amgen currently has an average rating of “Buy” and a consensus price target of $181.19.

The stock has a market cap of $123.34 billion and a PE ratio of 17.37. The stock has a 50 day moving average price of $155.87 and a 200 day moving average price of $152.93.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 28th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.60 by $0.30. The company had revenue of $5.53 billion for the quarter, compared to the consensus estimate of $5.32 billion. During the same quarter in the previous year, the business earned $2.48 earnings per share. Amgen’s revenue was up 9.8% compared to the same quarter last year. On average, analysts predict that Amgen Inc. will post $11.18 EPS for the current year.

In related news, EVP Madhavan Balachandran sold 30,000 shares of Amgen stock in a transaction dated Wednesday, May 4th. The stock was sold at an average price of $154.12, for a total value of $4,623,600.00. Following the completion of the sale, the executive vice president now directly owns 23,097 shares in the company, valued at approximately $3,559,709.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director David Baltimore sold 3,312 shares of Amgen stock in a transaction dated Friday, April 29th. The stock was sold at an average price of $157.21, for a total value of $520,679.52. Following the completion of the sale, the director now owns 32,350 shares of the company’s stock, valued at $5,085,743.50. The disclosure for this sale can be found here.

A number of large investors have added to or reduced their stakes in AMGN. Vanguard Group Inc. increased its stake in Amgen by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 44,916,785 shares of the medical research company’s stock valued at $7,291,342,000 after buying an additional 953,984 shares during the last quarter. Morgan Stanley increased its stake in Amgen by 5.4% in the fourth quarter. Morgan Stanley now owns 7,317,025 shares of the medical research company’s stock valued at $1,187,772,000 after buying an additional 373,979 shares during the last quarter. Bank of Montreal Can increased its stake in Amgen by 14.3% in the fourth quarter. Bank of Montreal Can now owns 2,648,382 shares of the medical research company’s stock valued at $429,912,000 after buying an additional 332,329 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Amgen by 0.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,438,620 shares of the medical research company’s stock valued at $395,860,000 after buying an additional 17,844 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its stake in Amgen by 1.9% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,168,882 shares of the medical research company’s stock valued at $354,157,000 after buying an additional 40,291 shares during the last quarter.

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.